Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- atherosclerosis cholestrols plasmas blood coronary heart diseases low-density lipoproteins kits assays assaying tools uptakes regulation
- Product Overview:
Low-density lipoproteins (LDL) is the major carrier of cholesterol in the blood, accounting for more than 60% of total plasma cholesterol. LDL is taken up by hepatic and extrahepatic tissues through LDL receptor-mediated endocytosis where it is internalized and degraded to free cholesterol and amino acids. Uptake of native and oxidized LDL by monocyte-derived macrophages in the vessel wall results in accumulation of cholesterol and formation of atherosclerotic plaques. The mechanism underlying the uptake of LDL by both hepatic tissue and cells of the cardiovascular system is not clearly understood. Thus, LDL uptake and its regulation are important therapeutic targets for atherosclerosis and related diseases. Cayman’s LDL Uptake Cell-Based Assay Kit provides a convenient tool for studying LDL uptake and regulation at cellular level. The kit employs human LDL conjugated to DyLight™ 550 as a fluorescent probe for detection of LDL uptake into cultured cells. A LDL receptor-specific polyclonal antibody and a DyLight™ 488-conjugated secondary antibody are included for identifying the distribution of LDL receptors.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.